RNAi screens for the identification and validation of novel targets: Current status and challenges

European Pharmaceutical Review

Volumn , Issue 6, 2010, Pages

  Seyhan, Attila A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REAGENT;

APOPTOSIS; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR LIBRARY; NONHUMAN; REVIEW; RNA INTERFERENCE; SCREENING TEST; VALIDATION PROCESS;

EID: 79952319821     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (77)

1. Dykxhoorn, D. M., Novina, C. D. & Sharp, P. A. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4, 457-467 (2003)
2. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004)
3. Zamore, P. D. & Haley, B. Ribo-gnome: the big world of small RNAs. Science 309, 1519-1524 (2005)
4. Chapman, E. J. & Carrington, J. C. Specialization and evolution of endogenous small RNA pathways. Nat Rev Genet 8, 884-896, doi:nrg2179 [pii] 10.1038/nrg2179 (2007)
5. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8, 129-138, doi:nrd2742 [pii] 10.1038/nrd2742 (2009)
6. Quon, K. & Kassner, P. D. RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets 13, 1027-1035, doi:10.1517/14728220903179338 (2009)
7. Seyhan, A. A., Alizadeh, B. N., Lundstrom, K. & Johnston, B. H. RNA interference-mediated inhibition of Semliki Forest virus replication in mammalian cells. Oligonucleotides 17, 473-484, doi:10.1089/oli.2007.0079 (2007)
8. Seyhan, A. A. et al. Complete, gene-specific siRNA libraries: production and expression in mammalian cells. RNA 11, 837-846, doi:11/5/837 [pii] 10.1261/rna.7285805 (2005)
9. Echeverri, C. J. & Perrimon, N. Highthroughput RNAi screening in cultured cells: a user's guide. Nat Rev Genet 7, 373-384, doi:nrg1836 [pii] 10.1038/nrg1836 (2006)
10. Seyhan, A. A. & Ryan, T. E. RNAi Screening for the Discovery of Novel Modulators of Human Disease. Curr Pharm Biotechnol, doi:BSP/CPB/EPub/ 0077-11-5 [pii] (2010)
11. Iorns, E., Lord, C. J., Turner, N. & Ashworth, A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6, 556-568, doi:nrd2355 [pii] 10.1038/nrd2355 (2007)
12. Boutros, M. & Ahringer, J. The art and design of genetic screens: RNA interference. Nat Rev Genet 9, 554-566, doi:nrg2364 [pii] 10.1038/nrg2364 (2008)
13. Mohr, S., Bakal, C. & Perrimon, N. Genomic screening with RNAi: results and challenges. Annu Rev Biochem 79, 37-64, doi:10.1146/annurev-biochem- 060408- 092949 (2010)
14. Birmingham, A. et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3, 199-204, doi:nmeth854 [pii] 10.1038/nmeth854 (2006)
15. Jackson, A. L. et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187, doi:rna.25706 [pii] 10.1261/rna.25706 (2006)
16. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23, 457-462, doi:nbt1081 [pii] 10.1038/nbt1081 (2005)
17. Lin, X. et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 33, 4527-4535, doi:33/14/4527 [pii] 10.1093/nar/gki762 (2005)
18. Sledz, C. A. & Williams, B. R. RNA interference and double-stranded-RNA-activated pathways. Biochem Soc Trans 32, 952-956, doi:BST0320952 [pii] 10.1042/BST0320952 (2004)
19. Falschlehner, C., Steinbrink, S., Erdmann, G. & Boutros, M. High-throughput RNAi screening to dissect cellular pathways: a how-to guide. Biotechnol J 5, 368-376, doi:10.1002/biot.200900277 (2010)
20. Bernards, R., Brummelkamp, T. R. & Beijersbergen, R. L. shRNA libraries and their use in cancer genetics. Nat Methods 3, 701-706, doi:nmeth921 [pii] 10.1038/ nmeth921 (2006)
21. Aza-Blanc, P. et al. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 12, 627-637, doi:S1097276503003484 [pii] (2003)
22. Murrow, L. M., Garimella, S. V., Jones, T. L., Caplen, N. J. & Lipkowitz, S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat, doi:10.1007/s10549-009-0571-2 (2009)
23. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437, doi:10.1038/nature02371 nature02371 [pii] (2004) (Pubitemid 38419689)
24. Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402, doi:S1535-6108(07)00262-0 [pii] 10.1016/j.ccr.2007.08. 030 (2007)
25. Brummelkamp, T. R. et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2, 202-206, doi:nchembio774 [pii] 10.1038/nchembio774 (2006)
26. Kolfschoten, I. G. et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-858, doi:S0092-8674(05)00397-1 [pii] 10.1016/j.cell.2005.04.017 (2005)
27. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 105, 20380-20385, doi:0810485105 [pii] 10.1073/pnas.0810485105 (2008)
28. Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110, doi:nature04687 [pii] 10.1038/nature04687 (2006).
29. Schlabach, M. R. et al. Cancer proliferation gene discovery through functional genomics. Science 319, 620-624, doi:319/5863/620 [pii] 10.1126/science.1149200 (2008)
30. Silva, J. M. et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319, 617-620, doi:319/5863/617 [pii] 10.1126/science. 1149185 (2008)
31. Westbrook, T. F. et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-848, doi:S0092-8674(05)00350-8 [pii] 10.1016/j.cell.2005.03.033 (2005)
32. Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S. & Sabatini, D. M. Genome-scale lossof- function screening with a lentiviral RNAi library. Nat Methods 3, 715-719, doi:nmeth924 [pii] 10.1038/nmeth924 (2006)
33. Downward, J. Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene 23, 8376-8383, doi:1208073 [pii] 10.1038/sj.onc.1208073 (2004)
34. Westbrook, T. F., Stegmeier, F. & Elledge, S. J. Dissecting cancer pathways and vulnerabilities with RNAi. Cold Spring Harb Symp Quant Biol 70, 435-444, doi:10.1101/sqb.2005.70.031 (2005) (Pubitemid 44124899)
35. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834, doi:S0092-8674(09)00316- X [pii] 10.1016/j.cell.2009.03.017 (2009)
36. Hattori, H. et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 110, 640-650, doi:blood-2006-11-059048 [pii] 10.1182/blood-2006-11-059048 (2007)
37. Whitehurst, A. W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819, doi:nature05697 [pii] 10.1038/nature05697 (2007)
38. Luo, J. & Elledge, S. J. Cancer: Deconstructing oncogenesis. Nature 453, 995-996, doi:453995a [pii] 10.1038/453995a (2008)
39. Brass, A. L. et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319, 921-926, doi:1152725 [pii] 10.1126/science.1152725 (2008)
40. Zhou, H. et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4, 495-504, doi:S1931-3128(08)00330-2 [pii] 10.1016/j.chom.2008.10.004 (2008)
41. Li, Q. et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 106, 16410-16415, doi:0907439106 [pii] 10.1073/pnas.0907439106 (2009)
42. Tai, A. W. et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5, 298-307, doi:S1931-3128(09)00061-4 [pii] 10.1016/j.chom.2009.02.001 (2009)
43. Randall, G. et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 104, 12884-12889, doi:0704894104 [pii] 10.1073/pnas.0704894104 (2007)
44. Hao, L. et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454, 890-893, doi:nature07151 [pii] 10.1038/nature07151 (2008)
45. Krishnan, M. N. et al. RNA interference screen for human genes associated with West Nile virus infection. Nature 455, 242-245, doi:nature07207 [pii] 10.1038/nature07207 (2008)
46. Qin, Q. M. et al. RNAi screen of endoplasmic reticulum-associated host factors reveals a role for IRE1alpha in supporting Brucella replication. PLoS Pathog 4, e1000110, doi:10.1371/journal.ppat.1000110 (2008)
47. Moffat, J. & Sabatini, D. M. Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol 7, 177-187, doi:nrm1860 [pii] 10.1038/nrm1860 (2006)
48. Perrimon, N. & Mathey-Prevot, B. Applications of high-throughput RNA interference screens to problems in cell and developmental biology. Genetics 175, 7-16, doi:175/1/7 [pii] 10.1534/genetics.106.069963 (2007)
49. Zhao, H. F. et al. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat Methods 2, 967-973, doi:nmeth812 [pii] 10.1038/nmeth812 (2005)
50. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H. & Williams, B. R. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5, 834-839, doi:10.1038/ncb1038 ncb1038 [pii] (2003) (Pubitemid 37087172)
51. Agrawal, S. & Kandimalla, E. R. Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol 22, 1533-1537, doi:nbt1042 [pii] 10.1038/nbt1042 (2004)
52. Sharma, S. & Rao, A. RNAi screening: tips and techniques. Nat Immunol 10, 799-804, doi:ni0809-799 [pii] 10.1038/ni0809-799 (2009)
53. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73 (1999)
54. Birmingham, A. et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6, 569-575, doi:nmeth.1351 [pii] 10.1038/nmeth.1351 (2009)
55. Boutros, M., Bras, L. P. & Huber, W. Analysis of cell-based RNAi screens. Genome Biol 7, R66, doi:gb-2006-7-7-R66 [pii] 10.1186/ gb-2006-7-7-R66 (2006)
56. Echeverri, C. J. et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 3, 777-779, doi:nmeth1006-777 [pii] 10.1038/nmeth 1006-777 (2006)
57. Lord, C. J., Martin, S. A. & Ashworth, A. RNA interference screening demystified. J Clin Pathol 62, 195-200, doi:jcp.2008.058735 [pii] 10.1136/jcp.2008.058735 (2009).
58. Haney, S. A. Increasing the robustness and validity of RNAi screens. Pharmacogenomics 8, 1037-1049, doi:10.2217/14622416.8.8.1037 (2007) (Pubitemid 47423691)
59. Maffia, A. M., 3rd, Kariv, I. I. & Oldenburg, K. R. Miniaturization of a Mammalian Cell- Based Assay: Luciferase Reporter Gene Readout in a 3 Microliter 1536-Well Plate. J Biomol Screen 4, 137-142 (1999)
60. Pfeifer, M. J. & Scheel, G. Long-term storage of compound solutions for high-throughput screening by using a novel 1536-well microplate. J Biomol Screen 14, 492-498, doi:1087057109335261 [pii] 10.1177/1087057109335261 (2009)
61. Borawski, J. & Gaither, A. The evolution of RNAi technologies in the drug discovery business. European Pharmaceutical Review 5, 35-39 (2010)
62. Stein, R. A. in Genetic Engineering and Biotechnology News Vol. 30 1, 18, 20-21 (2010)
63. Tyner, J. W. et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 106, 8695-8700, doi:0903233106 [pii] 10.1073/pnas.0903233106 (2009)
64. Freedman, V. H. & Shin, S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3, 355-359, doi:0092-8674(74)90050-6 [pii] (1974)
65. Anderson, S. N., Towne, D. L., Burns, D. J. & Warrior, U. A high-throughput soft agar assay for identification of anticancer compound. J Biomol Screen 12, 938-945, doi:12/7/938 [pii] 10.1177/1087057107306130 (2007)
66. Thierbach, R. & Steinberg, P. Automated soft agar assay for the high-throughput screening of anticancer compounds. Anal Biochem 387, 318-320, doi:S0003-2697(09)00054-2 [pii] 10.1016/j.ab.2009.01.029 (2009)
67. Fraser, A. G. et al. Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408, 325-330, doi:10.1038/35042517 (2000).
68. Gonczy, P. et al. Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome III. Nature 408, 331-336, doi:10.1038/35042526 (2000)
69. Bartscherer, K., Pelte, N., Ingelfinger, D. & Boutros, M. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell 125, 523-533, doi:S0092- 8674(06)00451-X [pii] 10.1016/j.cell.2006.04.009 (2006)
70. Boutros, M. et al. Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303, 832-835, doi:10.1126/science.1091266 303/5659/832 [pii] (2004). (Pubitemid 38174660)
71. Dietzl, G. et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151-156, doi:nature05954 [pii] 10.1038/nature05954 (2007)
72. Kambris, Z. et al. Drosophila immunity: a large-scale in vivo RNAi screen identifies five serine proteases required for Toll activation. Curr Biol 16, 808-813, doi:S0960-9822(06)01276-0 [pii] 10.1016/j.cub.2006.03.020 (2006)
73. Dickins, R. A. et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 39, 914-921, doi:ng2045 [pii] 10.1038/ng2045 (2007)
74. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864, doi:S0092- 8674(08)01302-0 [pii] 10.1016/j.cell.2008.09.061 (2008)
75. Bric, A. et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16, 324-335, doi:S1535-6108(09)00262-1 [pii] 10.1016/j.ccr.2009.08.015 (2009)
76. Xue, W. et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22, 1439-1444, doi:22/11/1439 [pii] 10.1101/gad.1672608 (2008)
77. Chen, Z., Stockton, J., Mathis, D. & Benoist, C. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc Natl Acad Sci U S A 103, 16400-16405, doi:0607854103 [pii] 10.1073/pnas.0607854103 (2006)